Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women

Maturitas

Volumn 23, Issue 3, 1996, Pages 285-291

  Baracat, Edmund ^a   Haidar, Mauro ^a   Castelo, Adauto ^a   Tufik, Sérgio ^a   De Lima, Geraldo Rodrigues ^a   Vieira, José Gilberto Henrique ^a   Peloso, Ulisses ^b   Casoy, Julio ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Wyeth Brazil   (Brazil)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

Bioavailability; Estradiol; Estrogen replacement therapy; Postmenopause; Transdermal

Indexed keywords

ESTRADIOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG UPTAKE; ESTROGEN THERAPY; FEMALE; HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 0030059907     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(95)00987-6     Document Type: Article

References (26)

1. Session DR, Kelly AC, Jewelewicz R. Current concepts in estrogen replacement therapy in the menopause. Fertil Steril 1993; 59: 277-284.
2. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy: a 10-years prospective study in the relationship to osteoporosis. Obstet Gynecol 1979; 53: 277-281.
3. Genant HK, Baylink DJ, Gallagher JC. Estrogens in the prevention of osteoporosis in postmenopausal women. Am J Obstet Gynecol 1989; 161: 1842-1846.
4. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75-78
5. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-1867.
6. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990; 75: 18S-25S.
7. Judd H. Efficacy of transdermal estradiol. Am J Obstet Gynecol 1987; 156: 1326-1331.
8. Utian WH. Transdermal estradiol overall safety profile. Am J Obstet Gynecol 1987; 156: 1335-1341.
9. Padwick ML, Endacott J, Whitehead MI. Efficacy acceptability and metabolic effects of transdermal estradiol in the management of postmenopausal women. Am J Obstet Gynecol 1985; 152: 1085-1091.
10. Steingold KA, Laufer L, Chetkowski RJ, et al. Treatment of hot flashes with transdermal estradiol administration J Clin Endocrinol Metabol 1985; 61: 627-631.
11. Selby PL, Peacock M. Dose dependent response of symptoms, pituitary and bone to transdermal oestrogen in postmenopausal women. Br Med J 1986; 293: 1337-1339.
12. Field CS, Ory SJ, Wahner HW, et al. Preventive effects of transdermal 17-beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993; 168: 114-121.
13. Erkkola R, Holma P, Jarvi T, et al. Transdermal oestrogen replacement therapy in a finnish population. Maturitas 1991; 13: 275-281.
14. Ribot C, Tremollieres F, Pouilles JM, et al. Preventive effects of transdermal administration of 17-beta-estradiol on postmenopausal bone loss: a 2-year prospective study. Gynecol Endocrinol 1989; 3: 259-268.
15. Stevenson JC, Cust MP, Ganger KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in post-menopausal women. Lancet 1990; 335: 265-269.
16. Whitehead MI, Padwick ML, Endacott J, Pryse-Davies J. Endometrial responses to transdermal estradiol in postmenopausal women. Am J Obstet Gynecol 1985; 152: 1079-1084.
17. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17-beta-estradiol: Comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol, 1985; 152: 1099-1106.
18. Baracat E, Tufik S, Castelo A, Rodrigues de Lima G, Haidar M, Casoy J, Peloso U. Comparative bioavailability study of a matrix versus a reservoir transdermal estradiol patch in healthy postmenopausal women. Curr Therap Res 1995; 56(4): 358-368.
19. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalentce of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics 1987; 15: 657-680.
20. Balfour JA, Heel RC. transdermal estradiol: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990; 40(4): 561-582.
21. Chetkowski RJ, Meldrun DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314: 1615-1620.
22. Laufer LR, Defazio JL, Lu JKH, et al. Estrogen replacement therapy by transdermal estradiol administration. Am J Obstet Gynecol 1983; 146: 533-540.
23. Corson SL. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. Int J Fertil 1993; 38: 79-91.
24. Miller-Bass K, Adashi EY. Current status and future prospects of transdermal estrogen replacement therapy. Fertil Steril 1990; 53(6): 961-974.
25. Nowogrodski J, Balanian L, Carrara D, Estrin D, Stefano FJE. First pass metabolism in transdermal administration of estradiol. Acta Physiol Pharmacol Latinoamer 1989; 39: 70.
26. Figueroa-Casas PR, Alfonsin A, Arrighi A, et al. Use of a new transdermal delivery system for estrogen replacement therapy in postmenopausal women. Maturitas 1995; 20: 139-144.